McClung NM et al. Estimated Number of Cases of High-Grade Cervical Lesions Diagnosed among Women - United States, 2008 and 2016. MMWR Morb Mortal Wkly Rep 2019; 68:337
Drolet M, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programs: updated systematic review and meta-analysis. Lancet 2019: 394:497.
Jena, AB et al. Incidence of sexually transmitted infections after human papillomavirus vaccination among adolescent females. JAMA Intern Med. 2015:175(4):617-623.
Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915.
Joura EA, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl. 800S Med 2015; 372:711.
What parents should know about HPV vaccine safety and Effectiveness. Centers for Disease Control and Prevention.
https://www.cdc.gov/vaccines/partners/downloads/teens/vaccine-safety.pdf April 22, 2016.
Crowe E, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: a case-control study nested within a population-based screening program in Australia. BMJ 2014: 348:q 1458.
Kjaer SK, et al. Real-World Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer. J Natl Inst 2021: 113:1329.
Falcaro M. et al. Effects of the national HPV vaccination program in England, UK, on cervical cancer and grade 3 intraepithelial neoplasia incidence: a register-based observational study. Lancet, 11/3/2021.
Saraiya M, et al. US assessment of HPV types in cancers: implications for current and 9 valent HPV vaccines. J Natl Cancer Inst. 2015; 107(6):djv086.doi.10.1093/jnci/djv086
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
National Center for Immunization and Respiratory Diseases
National Center for Chronic Disease Prevention and Health Promotion